Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

"Sanofi in talks to sell stake in consumer healthcare unit to CD&R" was originally created and published by Pharmaceutical ...

Sanofi SAN-1.01%decrease; red down pointing triangle moved ahead with a plan to sell a controlling stake in its consumer-healthcare unit ... business that is home to brands such as Allegra ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion ... With a portfolio of iconic brands, such as Allegra, Doliprane ...

Sanofi and CD&R partner to ... to create a French-headquartered, global consumer healthcare champion. Opella is differentiated by the quality of its brand portfolio and its highly skilled and ...

To combat this, allergy medication Allegra created Allegra Airways, a website designed to help find and map real-time routes ...

Sanofi's consumer health unit, valued at $17.4 billion. Opella serves over 500M consumers globally with top brands like Allegra and Dulcolax. Sanofi SA SNY and private equity Clayton Dubilier ...

Sanofi and CD&R enter exclusive negotiations ... innovation and growth to create a French-headquartered, global consumer healthcare champion. Opella is differentiated by the quality of its brand ...